USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AMT, INC.
City: CHERRY HILL
State: NJ
Zip+4: 08003
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (609) 795-4560

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $677,688.00 11
SBIR Phase II $638,167.00 2
STTR Phase I $100,000.00 2
STTR Phase II $278,132.00 1

Award List:

STABLE ANTITUMOR PLATINUM COMPLEXES

Award Year / Program / Phase: 1983 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul Schwartz
Award Amount: $72,380.00

NOVEL APPROACHES TO FASIL POLYMERS

Award Year / Program / Phase: 1983 / SBIR / Phase I
Agency / Branch: DOD / USAF
Principal Investigator:
Award Amount: $59,891.00

NOVEL APPROACHES TO FASIL POLYMERS

Award Year / Program / Phase: 1984 / SBIR / Phase II
Agency / Branch: DOD / USAF
Principal Investigator:
Award Amount: $305,000.00
Abstract:
Fluorroalkylarylenesiloxanylene (fasil) polymers possess excellent themal stability, low emperatue, and hydrocarbon solvent resistance. polymers based on fasil have extensive promise for military and commercial aerospace applications if they could be reliably and efficiently produced. the program… More

STABLE ANTITUMOR PLATINUM COMPLEXES

Award Year / Program / Phase: 1985 / SBIR / Phase II
Agency: HHS
Principal Investigator: Paul Schwartz
Award Amount: $333,167.00
Abstract:
The objective of this study is to prepare antineoplastic platinum complexes with stabilities in solution greater thanthat of 4-carboxyphthalato(1,2-diaminocyclohexane) platinum (nsc 271674;dachpt). nsc 271674 is a cisplatin analog invented by the applicant and now in phase ii clinical trials at… More

THE PROVEN CLINICAL EFFECTIVENESS OF CISPLATIN AS WELL AS SEVERAL SECOND GENERATION ANALOGS HAS ESTABLISHED THE ROLE OF METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Devinder gill , PRINCIPAL INVESTIGATOR
Award Amount: $49,885.00
Abstract:
The proven clinical effectiveness of cisplatin as well as several second generation analogs has established the role of metal coordination compounds in cancer chemotherapy. complexes of metals other than platinum have been often poorly designed because they were modeled after the active platinum… More

THE OBJECTIVE OF THIS STUDY IS TO SYNTHESIZE, CHARACTERIZE, AND EVALUATE BIOLOGICAL PROPERTIES OF POLYMERIC PLATINUM COMPLEXES IN AN EFFORT TO ENHANCE SOLUBILITY AND STABILITY WHILE REDUCING TOXICITY AND OBTAINING GREATER SUSTAINED ACTIVITY THAN THAT

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Devinder gill , PRINCIPAL INVESTIGATOR
Award Amount: $49,839.00
Abstract:
The objective of this study is to synthesize, characterize, and evaluate biological properties of polymeric platinum complexes in an effort to enhance solubility and stability while reducing toxicity and obtaining greater sustained activity than that found with active, structurally related,… More

THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter andrulis jr , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The complex 4-carboxyphthalato (1, 2-diaminocyclohexane) platinum (nsc 271674; dach-pt) has undergone limited clinical trials. designed as an alternative therapy to cisplatin, it has demonstrated substantially reduced toxicity and enhanced activity in tumors resistant to cisplatin in animals… More

NEW TARGET-DIRECTED PT-PORPHYRIN ANTICANCER DRUGS

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul schwartz phd
Award Amount: $46,000.00
Abstract:
The objective of this project is to improve the selectivity of action of platinum antitumor agents. platinum compounds have shown activity in many types of tumors, but severe dose-limiting side effects have affected their clinical utility. by directing these agents more specifically to tumor sites,… More

MECHANISM-BASED ELASTASE INHIBITORS

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Clare biswas phd
Award Amount: $50,000.00
Abstract:
Synthetic elastase inhibitors for use in the treatment of emphysema will be developed. in phase i, new mechanism-based elastase inhibitors will be synthesized, characterized, and studied as inhibitors of elastase in vitro. these inhibition studies will analyze both the reversible behavior of the… More

POLYMERIC DELIVERY SYSTEMS FOR ANTIRETROVIRAL AGENTS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Devinder S Gill
Award Amount: $49,855.00
Abstract:
The goal of this phase i research is to design, synthesize, develop, and evaluate the in vitro efficacy of a new class of polymeric "targeted" prodrugs of azt. the overall objective of this program is to create new anti-aids prodrugs that will possess markedly enhanced antiviral activity, low… More

SOLUBILIZATION AND SUSTAINED DELIVERY OF ANTITUMOR AGENTS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Devinder S Gill
Award Amount: $49,838.00
Abstract:
The overall objective is to provide a new drug delivery system and to enhance the solubility of existing compounds that exhibit excellent antitumor properties but are insoluble in water. aqueous solubility is essential for i.v. administration of antitumor drugs. phase i research will solubilize… More

MICROWAVE AIDED LIPOSUCTION

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rosen, Danielle
Award Amount: $100,000.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Danielle Rosen
Award Amount: $100,000.00

ENDOSCOPIC LIGHT SOURCE FOR PDT

Award Year / Program / Phase: 2001 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF PENNSYLVANIA
Principal Investigator: Richard A. Hsi
Award Amount: $278,132.00
RI Contact: N/A
Abstract:
DESCRIPTION (Verbatim from the Applicant's Abstract): We propose to continue to develop and test a self-contained light delivery device for use in photodynamic therapy (PDT) for Barrett's esophagus. This device employs distally located semiconductor lasers at the end of a thin… More